John Sheridan compensation by year
TANDEM DIABETES CARE Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $365,000 | $375,000 | $386,250 | $500,000 | $600,000 | $690,000 | $710,700 | $710,700 | $732,021 | $790,583 |
| Bonus | $109,500 | $164,813 | $0 | $0 | $60,385 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $1,079,971 | $2,069,974 | $3,452,202 | $3,663,250 | $7,132,756 | $5,367,796 |
| Option awards | $523,351 | $53,546 | $1,197,532 | $9,319,134 | $1,619,976 | $2,069,998 | $1,700,348 | $0 | $0 | $0 |
| Non-equity incentive | $0 | $0 | $350,863 | $738,225 | $422,692 | $905,370 | $359,418 | $266,513 | $650,021 | $674,090 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $14,675 | $2,772 | $2,772 | $3,578 | $7,715 | $4,540 | $155,847 | $11,140 | $11,440 | $26,034 |
| Total | $1,012,526 | $596,131 | $1,937,417 | $10,560,937 | $3,790,739 | $5,739,882 | $6,378,515 | $4,651,603 | $8,526,238 | $6,858,503 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TANDEM DIABETES CARE INC DEF 14A filed April 7, 2026, accession 0001438133-26-000034, and prior-year filings. Open the filing on EDGAR.
How this page was built: the TANDEM DIABETES CARE INC filed document, accession 0001438133-26-000034. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 119,206 | $2,620,148 | — |
| PSU | 119,204 | $2,620,104 | — |
| PSU | 71,787 | $1,577,878 | — |
| RSU | 35,894 | $788,950 | — |
| RSU | 10,943 | $240,527 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in TANDEM DIABETES CARE INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
17 Form 4 lines since the FY2025 proxy (filed April 7, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-15 | Exercise or conversion | — | 9,934 | $0.00 | 165,315 |
| 2026-08-15 | Exercise or conversion | — | 5,982 | $0.00 | 158,425 |
| 2026-08-15 | Exercise or conversion derivative | — | 9,934 | $0.00 | 69,537 |
| 2026-08-15 | Exercise or conversion derivative | — | 5,982 | $0.00 | 17,947 |
| 2026-08-15 | Tax withholding | — | 3,044 | $22.72 | 155,381 |
| 2026-08-15 | Tax withholding | — | 5,055 | $22.72 | 160,260 |
| 2026-05-29 | Grant or award derivative | — | 191,103 | $0.00 | 191,103 |
| 2026-05-15 | Grant or award | — | 1,336 | $10.90 | 152,443 |
The 8 most recent of 17 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments TANDEM DIABETES CARE discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and resignation for good reason | $3,162,332 | $3,649,625 | — | $6,811,957 |
| Change in control and involuntary termination | $3,162,332 | $3,649,625 | — | $6,811,957 |
Per the Potential Payments Upon Termination or Change in Control table in TANDEM DIABETES CARE INC's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
TANDEM DIABETES CARE’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| John Sheridan · this page | President and Chief Executive Officer | $6,858,503 |
| Mark Novara | Executive Vice President and Chief Commercial Officer | $2,204,612 |
| Leigh Vosseller | Executive Vice President, Chief Financial Officer and Treasurer | $2,181,894 |
| Elizabeth Gasser | Executive Vice President and Chief Strategy and Product Officer | $1,747,944 |
| Shannon Hansen | Executive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary | $1,747,901 |
Board service
TANDEM DIABETES CARE board · FY2021–FY2025How this board is paid
Company policy: TANDEM DIABETES CARE pays directors a $60,000 cash retainer and $180,000 in equity. As stated in TANDEM DIABETES CARE's FY2025 proxy.
The full TANDEM DIABETES CARE compensation record
free company briefThis page is one person within TANDEM DIABETES CARE's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the TANDEM DIABETES CARE proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order TANDEM DIABETES CARE's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TANDEM DIABETES CARE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TNDM
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.